CO5670356A2 - Programa de dosificaicon para un nuevo agente anticanceroso - Google Patents
Programa de dosificaicon para un nuevo agente anticancerosoInfo
- Publication number
- CO5670356A2 CO5670356A2 CO06015089A CO06015089A CO5670356A2 CO 5670356 A2 CO5670356 A2 CO 5670356A2 CO 06015089 A CO06015089 A CO 06015089A CO 06015089 A CO06015089 A CO 06015089A CO 5670356 A2 CO5670356 A2 CO 5670356A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitor
- new anti
- mammal
- interval
- procedure
- Prior art date
Links
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 9
- 239000003112 inhibitor Substances 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 1
- 108091006082 receptor inhibitors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un procedimiento para tratar la sobreexpresión del receptor de erbB2 en un mamífero que necesite dicho tratamiento, comprendiendo dicho procedimiento: (a) administrar a dicho mamífero una cantidad terapéuticamente eficaz de un primer inhibidor del receptor de erbB2; y (b) administrar posteriormente a dicho mamífero, después de un intervalo que comprende menos de 24 horas, de una a seis cantidades terapéuticamente eficaces de un segundo inhibidor del receptor de erbB2.2.- El procedimiento de la reivindicación 1, en el que se administra una cantidad terapéuticamente eficaz de dicho segundo inhibidor del receptor de erbB2 en la etapa (b) de dicho procedimiento.3.- El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que intervalo de la etapa (b) de dicho procedimiento es menor de 12 horas.4.- El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que intervalo de la etapa (b) de dicho procedimiento es menor de 1 hora.5.- El procedimiento de una cualquiera de las reivindicaciones anteriores, en el que el primer inhibidor en (a) es el mismo que el segundo inhibidor en (b).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49591903P | 2003-08-18 | 2003-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5670356A2 true CO5670356A2 (es) | 2006-08-31 |
Family
ID=34193358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06015089A CO5670356A2 (es) | 2003-08-18 | 2006-02-15 | Programa de dosificaicon para un nuevo agente anticanceroso |
Country Status (18)
Country | Link |
---|---|
US (1) | US20050119288A1 (es) |
EP (1) | EP1658080A1 (es) |
JP (1) | JP2007502807A (es) |
KR (2) | KR20080014144A (es) |
CN (1) | CN1838959A (es) |
AR (1) | AR045268A1 (es) |
AU (1) | AU2004264726A1 (es) |
BR (1) | BRPI0413745A (es) |
CA (1) | CA2536140A1 (es) |
CO (1) | CO5670356A2 (es) |
IL (1) | IL173127A0 (es) |
MX (1) | MXPA06001989A (es) |
NO (1) | NO20061252L (es) |
RU (1) | RU2328287C2 (es) |
SG (1) | SG135193A1 (es) |
TW (1) | TW200522966A (es) |
WO (1) | WO2005016347A1 (es) |
ZA (1) | ZA200600517B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2472341C (en) | 2002-02-01 | 2011-06-21 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
MXPA06001767A (es) * | 2003-08-14 | 2006-05-12 | Array Biopharma Inc | Analogos de quinazolina como inhibidores de la tirosina quinasa receptora. |
DE602004004553T2 (de) | 2003-09-19 | 2007-10-25 | Astrazeneca Ab | Chinazolinderivate |
DK1746999T3 (da) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amider |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
EP1896030A1 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
CN102772358A (zh) * | 2005-06-16 | 2012-11-14 | 美瑞德生物工程公司 | 药物组合物及其用途 |
JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
US8945573B2 (en) * | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
EP1962839A4 (en) * | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
CA2632194C (en) | 2005-11-15 | 2012-01-03 | Array Biopharma Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
EP2010911A4 (en) * | 2006-03-31 | 2009-05-13 | Massachusetts Inst Technology | TREATMENT OF TUMORS EXPRESSING EGF MUTANT RECEPTORS |
AU2007234379A1 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
CN103330694A (zh) | 2006-11-14 | 2013-10-02 | 阿里亚德医药股份有限公司 | 口服制剂 |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
NZ580868A (en) * | 2007-04-10 | 2011-07-29 | Myriad Pharmaceuticals Inc | Dosages and methods for the treatment of cancer |
WO2008124822A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Method of treating brain cancer |
AU2008236994A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating melanoma |
WO2008124826A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating cancer |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
WO2009137714A2 (en) * | 2008-05-07 | 2009-11-12 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
US20100087459A1 (en) * | 2008-08-26 | 2010-04-08 | Leonid Metsger | Forms of lapatinib compounds and processes for the preparation thereof |
CN104447995A (zh) * | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
WO2015115635A1 (ja) | 2014-01-31 | 2015-08-06 | 凸版印刷株式会社 | 生体分子解析キット及び生体分子解析方法 |
AU2016343817B2 (en) | 2015-10-28 | 2021-05-27 | Tva (Abc), Llc | SSTR-targeted conjugates and particles and formulations thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1292591T3 (da) * | 2000-06-22 | 2005-05-30 | Pfizer Prod Inc | Bicykliske derivater til behandling af abnorm cellevækst |
GEP20063872B (en) * | 2001-12-12 | 2006-07-10 | Pfizer Prod Inc | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production |
MXPA04004107A (es) * | 2001-12-12 | 2004-07-23 | Pfizer Prod Inc | Moleculas pequenas para el tratamiento del crecimiento celular anormal. |
AU2003291394B2 (en) * | 2002-11-20 | 2009-06-25 | Array Biopharma, Inc | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
KR20050085749A (ko) * | 2002-12-18 | 2005-08-29 | 화이자 프로덕츠 인크. | 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체 |
-
2004
- 2004-08-06 KR KR1020087000092A patent/KR20080014144A/ko not_active Application Discontinuation
- 2004-08-06 SG SG200706063-5A patent/SG135193A1/en unknown
- 2004-08-06 CA CA002536140A patent/CA2536140A1/en not_active Abandoned
- 2004-08-06 MX MXPA06001989A patent/MXPA06001989A/es not_active Application Discontinuation
- 2004-08-06 RU RU2006102125/14A patent/RU2328287C2/ru not_active IP Right Cessation
- 2004-08-06 KR KR1020067003190A patent/KR20060037447A/ko not_active Application Discontinuation
- 2004-08-06 BR BRPI0413745-0A patent/BRPI0413745A/pt not_active IP Right Cessation
- 2004-08-06 EP EP04744217A patent/EP1658080A1/en not_active Withdrawn
- 2004-08-06 CN CNA200480023705XA patent/CN1838959A/zh active Pending
- 2004-08-06 JP JP2006523695A patent/JP2007502807A/ja not_active Withdrawn
- 2004-08-06 WO PCT/IB2004/002580 patent/WO2005016347A1/en active Application Filing
- 2004-08-06 AU AU2004264726A patent/AU2004264726A1/en not_active Abandoned
- 2004-08-17 AR ARP040102941A patent/AR045268A1/es not_active Application Discontinuation
- 2004-08-17 US US10/919,831 patent/US20050119288A1/en not_active Abandoned
- 2004-08-17 TW TW093124706A patent/TW200522966A/zh unknown
-
2006
- 2006-01-12 IL IL173127A patent/IL173127A0/en unknown
- 2006-01-18 ZA ZA200600517A patent/ZA200600517B/xx unknown
- 2006-02-15 CO CO06015089A patent/CO5670356A2/es not_active Application Discontinuation
- 2006-03-17 NO NO20061252A patent/NO20061252L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200600517B (en) | 2007-02-28 |
CA2536140A1 (en) | 2005-02-24 |
CN1838959A (zh) | 2006-09-27 |
RU2006102125A (ru) | 2007-09-27 |
JP2007502807A (ja) | 2007-02-15 |
NO20061252L (no) | 2006-05-16 |
MXPA06001989A (es) | 2006-05-17 |
IL173127A0 (en) | 2006-06-11 |
BRPI0413745A (pt) | 2006-10-24 |
AR045268A1 (es) | 2005-10-19 |
EP1658080A1 (en) | 2006-05-24 |
WO2005016347A1 (en) | 2005-02-24 |
AU2004264726A1 (en) | 2005-02-24 |
RU2328287C2 (ru) | 2008-07-10 |
US20050119288A1 (en) | 2005-06-02 |
KR20080014144A (ko) | 2008-02-13 |
KR20060037447A (ko) | 2006-05-03 |
TW200522966A (en) | 2005-07-16 |
SG135193A1 (en) | 2007-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
EA201070740A1 (ru) | Способ лечения перелома кости антителами против склеростина | |
AR039416A1 (es) | Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado | |
BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
ECSP056156A (es) | Procedimiento y composiciones farmacéuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
AR060089A1 (es) | Tratamiento del dolor | |
PE20080349A1 (es) | Estructuras de cristal de inhibidores sglt2 y procesos para preparar los mismos | |
BR0111800A (pt) | Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus | |
CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
AR051446A1 (es) | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) | |
PE20060594A1 (es) | Composicion farmaceutica que contiene un agonista de ppar | |
EA200800755A1 (ru) | Ikk ингибиторы, предназначенные для лечения эндометриоза | |
NO20083885L (no) | Fremgangsmate for behandling av inflammatoriske sykdommer | |
BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
CO5590913A2 (es) | Terapia de combinacion antivirica | |
BRPI0919020A2 (pt) | Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris | |
EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
RS53491B1 (en) | Compositions for the treatment of centrally mediated nausea and vomiting | |
NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
EA200101089A1 (ru) | Новый способ лечения | |
EA200800766A1 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |